BioWorld Insider Podcast
by www.bioworld.com
One-on-one with medical innovatorsBreakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.
Episodes
-
Finding a better, longer-lasting fix in opioid overdose
The opioid crisis may not be front and center anymore, but it’s raging still. A major problem is that overdose-reversal drugs don’t last long enough to help users who opt out of hospital treatment after they are revived. Elysium Therapeutics Inc. CEO Greg Sturmer talks with Randy Osborne about…
more -
Esperion Therapeutics CEO Sheldon Koenig
Starting with the Clear Outcomes study in 2023, which gave Esperion Therapeutics immediate success with more than 1 billion impressions globally, the company has been creating a pipeline to keep its positive momentum going. Esperion developed and is commercializing the only U.S. FDA approved…
more -
Trying this at home: Bioxcel steps closer to an sNDA for Igalmi
Bioxcel Therapeutics Inc.’s phase III results in bipolar disorders or schizophrenia could bring Igalmi (BXCL-501) out of the clinic and into patients' homes for easier treatment. Vimal Mehta, Bioxcel CEO, talks about the potential with Lee Landenberger in the latest BioWorld Insider podcast.…
more -
The importance of balancing AI and people in drug development
More and more, artificial intelligence is becoming inseparable from drug development. But it needs to be well integrated with the right people and support technologies in order to be successful, according to Josep Bassaganya-Riera, the founder and CEO of Nimmune Biopharma Inc. Nimmune has…
more -
Two CEOs discuss bracing for tariffs, NIH grant cuts and gifting China biopharma leadership position
As pharma deals with the impact of NIH grant cuts and what could follow with the imposition of tariffs, Robert Williamson, CEO of Triumvira Immunologics Inc., and Hernan Bazan, CEO of South Rampart Pharma LLC, brought their extensive experience in the industry to the podcast. Their concerns…
more -
As biopharma investments stumble, med tech surges
The biopharma sector is still trying to get its wind and resume its once-powerful investment ways. Medical technology has sidestepped much of biopharma’s issues by being more flexible along the development path, according to BioWorld MedTech Editor Annette Boyle in this edition of the podcast.…
more -
Mega money well spent? Mammoth mergers fall short of the dream
Billion-dollar M&As are commonplace now, but not too long ago they were a rarity. So many have occurred in the past few years, they’ve become the norm. But were all these multi-billion-dollar mega mergers worth the money? Karen Carey, BioWorld’s senior managing editor and chief analyst, crunched...
-
Healing the health divide for women
As a new BioWorld new investigative report shows, decades of research excluding women from clinical trials and investment decisions made in male-dominated boardrooms have led to half the world’s health needs being underserved. Of the drug development companies working on women's health solutions,...
-
Modifi gets creative on the rocky road to a multibillion-dollar buyout
Modifi Biosciences Inc. was recently acquired by Merck & Co. Inc. for $30 million up front. Modifi shareholders could receive milestones of up to $1.3 billion. It all happened in the dizzyingly short span of a little more than two years. Modifi’s founder, Ranjit Bindra, and a small group of...
-
A quantum leap into the future of drug development
In the newest BioWorld Insider podcast, Victoria Lipinska, the America's lead for Quantum Innovation Centers at IBM Quantum, talks about the future of drug development using quantum computing. “The new technology is a completely different branch of computing as opposed to what we know right now,...
-
Gene and cell therapies will propel innovation, says Astellas CCO
Gene and cell therapies will drive innovation for the next 10 years, Claus Zieler, the chief commercial officer at Astellas Pharma Inc., said in this episode of the BioWorld Insider podcast. Developers are on the cusp of breakthroughs because a gene can now be replaced “and that means we can...
-
Capricor’s CEO pursues a BLA and talks rare disease
Capricor Therapeutics Inc. just wrapped up a visit with the U.S. FDA and is prepping to file a BLA in October for its Duchenne muscular dystrophy treatment. Linda Marbán, Capricor’s CEO, is the guest on the newest BioWorld Insider podcast and she talks about deramiocel (CAP-1002), the company’s...
-
The first half of 2024 was strong as M&As and financings dominate
Karen Carey, BioWorld managing editor and chief analyst, takes a look at the numbers from the first half of 2024. She finds the first six months to be healthy for the biopharma market while the rest of the year is populated with question marks that include the U.S. presidential election and...
-
The cost of delays in development and sales: It’s probably not what you think
Two costs of developing drug candidates have been upended by new research from the Tufts University School of Medicine’s Center for the Study of Drug Development. New data have produced some very different numbers than you might expect in the cost of a single day of a clinical trial and of…
more -
ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference
Chris Bardon, a co-managing partner at MPM Bioimpact who manages the firm’s Bioimpact Equities and Oncology Impact funds, shares her insights into the upcoming American Society of Clinical Oncology (ASCO) conference in Chicago. She talks about the major trends in oncology, including development…
more -
Fibrobiologics walks the unconventional financing path
A non-traditional route for financing has been the path to success for Fibrobiologics Inc. In the newest BioWorld Insider podcast, CEO Pete O’Heeron offers insight into the company’s unusual path to a Nasdaq listing in January. SPACs, reverse mergers and traditional IPOs weren’t attractive enough...
-
Back to fundamentals: The latest numbers point to better times
BioWorld Managing Editor Karen Carey joins the podcast to talk about the numbers from the first quarter of 2024, along with a look back at some 2023 deals and indicators that signal better times are on the way. Financings for the quarter were better than expected, sporting some of the best…
more -
Mark McKenna storms back with Mirador and eyes the development landscape
In one of the biggest financings of the year so far, former Prometheus Biosciences Inc. CEO Mark McKenna helped raise $400 million to launch a new company, Mirador Therapeutics Inc. He didn’t sit on the sidelines for long after Merck & Co. Inc. bought Prometheus for $10.8 billion in 2023. He...
-
Biopharma execs seek to avoid pain points in AI integration
Because artificial intelligence is such a new technology it comes with a mountain of unknowns. Integrating it into a pharmaceutical company presents a unique series of challenges, as a new survey from Verix shows. The report is based on responses from directors, vice presidents and C-suite...
-
Six biopharma executives consider a tough 2023 and are hopeful for a better 2024
One aspect of 2023 our group of executives completely agreed on: the past year was tough financially. And they all foresee a more vibrant year ahead for the market. Giving all of them hope were technological breakthroughs such as artificial intelligence, game changing weight loss drugs, the…
more -
AI: driving drug development from effective to remarkable
Google’s Scott Penberthy joins the podcast for a visionary discussion that scans the horizon for startling changes artificial intelligence will bring to drug development in the relatively near future. Among the gems and eyebrow raisers is talk of dramatic reductions in the time it takes to…
more -
The struggle is real: The first half of 2023 was an uphill climb
Guests Karen Carey, BioWorld’s managing editor, and Mike Ward, Clarivate’s global head of Life Sciences and Healthcare Thought Leadership, discuss the deals, financing and M&A landscape for the first half of 2023 and how U.K. biopharmas are faring post Brexit. Download transcript
-
The biosimilars challenge to Humira revs up
Guests BioWorld Regulatory Editor Mari Serebrov and Tom Newcomer, Samsung Bioepis vice president and head of U.S. market access, discuss the launch of biosimilars that are taking on a blockbuster. Download transcript
-
Preventing opioid overdoses with a smart patch
Brad Holden, CEO of Resilient Lifescience, explains how the device works for overdoses as well as other potential applications for this new technology. Download transcript
-
Better times ahead for the biopharma sector? Could be, the new numbers say
Karen Carey, BioWorld’s managing editor and senior data analyst, and Tim Shannon, a general partner at Canaan, break down the numbers from first quarter of 2023. Download transcript
-
Radiopharmaceuticals: The next big disrupter?
BioWorld Staff Writer Tamra Sami talks about the science behind radiopharmaceuticals, the supply chain vulnerabilities, the regulatory landscape, the patient journey and therapies in the pipeline. Download transcript
-
Cambrian carves out a new niche as it works to keep people from getting sick
James Peyer, the CEO of Cambrian Biopharma Inc., talks about anti-aging therapies, a business model that fits the new field of geroscience. Download transcript
-
Rethinking obesity: Fitness may be more directly linked to health than weight
BioWorld Science Managing Editor Anette Breindl discusses her new analysis of multiple studies related to weight loss, metabolic health and fitness that in many ways go against mainstream theories about obesity. Download transcript
-
Looking ahead to 2023: CEOs contemplate the new normal
Guests Karen Zaderej, CEO of Axogen Inc., Sean Bohen, CEO of Olema Oncology Inc., Rob Ross, the CEO of Surface Oncology Inc., and Rob Etherington, the CEO of Clene Nanomedicine Inc., speak about adapting their companies to the market’s new realities. Download transcript
-
Psychedelic evolution: Mindset Pharma looks to change mental health treatment
James Lanthier, the CEO of Mindset Pharma Inc., talks about developing next-generation psychedelic medicines to treat neurological and psychiatric disorders. Download transcript
-
$1B+ biopharma deals keep values afloat, even amid muted volume
BioWorld Senior Analyst Karen Carey chats about the collision of a volatile economic climate and big biopharma deals. Download transcript
-
Extending the human lifespan
Extending the Human Lifespan, a BioWorld special report, examines the companies developing “Fountain of Youth” drugs. In this episode, the writers discuss this scientific holy grail. Download transcript
-
New therapies vie to change the fatal course of amyotrophic lateral sclerosis
Executives from Amylyx Pharmaceuticals Inc. and Clene Inc., along with a key Penn State ALS expert, discuss what the future of medicine holds for patients. Download transcript
-
Biopharma’s correction? 2022 1Q investments are both up and down
BioWorld Senior Analyst Karen Carey explores the newest data and where it is leading. Download transcript
-
Who advises the CDC on big COVID decisions?
Infection control expert William Schaffner of the Vanderbilt University School of Medicine joins to discuss the CDC’s Advisory Committee on Immunization Practices and how COVID-19 put the committee’s schedule into overdrive. Download transcript
-
Long COVID: Potentially the next public health crisis
BioWorld Senior Science Editor Anette Breindl goes in depth about how long COVID-19 emerged and is being defined. Download transcript
-
What happens when your inventor is an artificial intelligence?
Guests Ryan Abbott, a professor of law and medicine, as well as the leader of the Artificial Inventor Project, and Jim Belfiore, senior vice president of innovation at Clarivate plc, have a discussion about the brave new world AI is creating. Download transcript
-
Aduhelm’s hard lessons and what it means for other Alzheimer’s drugs
Insights into the controversial drug come from guests Michael Agadjanyan, president of Nuravax Inc., which is developing antibodies for preventing Alzheimer’s and Parkinson’s diseases, along with Robert Glanzman, chief medical officer of Clene Nanomedicine Inc. Download transcript
-
Another record year for biopharma financings bodes well for 2022
A conversation with Kleanthis Xanthopoulos, a co-founder and executive chairman of Shoreline Biosciences, and Joe Hernandez, CEO and executive chairman of Blue Water Vaccines, who have founded or led eight health care and pharmaceuticals companies. Download transcript
-
Supply Chain Geeky: Managing through the challenges of COVID-19 with an eye to what’s at stake
Paul Testa, executive vice president for operations and supply chain at Tokyo-based Kyowa Kirin, on the dramatic importance of continuity, reliability of supply, business process and automation. Download transcript
-
Regulatory Gemish: COVID-19’s big impacts on the FDA and beyond
Peter Pitts, president of the Center for Medicine in the Public Interest, on how government regulation seems like a slow but in actuality moves more quickly than understood. Download transcript
-
Reality check: How did industry develop COVID-19 vaccines and drugs so fast?
BioWorld Regulatory Editor Mari Serebrov puts the pandemic and the science into perspective. Download transcript
-
Merck’s new COVID-19 pill will save lives, but at what price?
Joseph Allen, executive director of the Bayh-Dole Coalition, explains how molnupiravir, from Ridgeback Biotherapeutics, and partner Merck & Co. Inc., may have never had a chance to move out of the university onto pharmacy shelves without the government’s support. Download transcript
-
Newly approved cervical cancer drug Tivdak gives patients a new option
The approval of antibody-drug conjugate Tivdak (tisotumab vedotin) for treating cervical cancer and the future of Genmab A/S are the subjects with the company's president and CEO, Jan van de Winkel. Download transcript
-
DNA vaccines: a better path to taming the pandemic?
An in-depth conversation with Lucio Rovati, CEO and chief scientific officer of Italy’s Rottapharm Biotech as they tackle the new world of DNA vaccines. Download transcript
-
Rising to the COVID-19 challenge, clinical trials evolve
Laurie Halloran, president and CEO of Boston-based Halloran Consulting, shares her thoughts on the impact of COVID-19 on clinical trials. Download transcript
-
A ‘Revolution’ in drugging the undruggable hits a speed bump but motors on
Mark Goldsmith, Revolution Medicines Inc. president, CEO and chairman, talks about grappling with RAS mutations. Download transcript
-
As dementia cases grow, biomarkers and new therapies key to unlocking treatment
Howard Fillit, founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation, shares his insights on the impact of financial investments driving these therapies. Download transcript
-
As biopharma deals keep pace, M&A volumes languish
Biopharma deal-making activity, a closely watched marker of industry health, was alive and well in the second quarter. BioWorld Senior Analyst Karen Carey sifts through the numbers. Download transcript
-
Iteos brings Glaxosmithkline a third checkpoint-targeting antibody in a $2B deal
Michel Detheux, president and CEO of Iteos Therapeutics Inc., discusses what his company brings GSK in a massive new deal. Download transcript
About this show
One-on-one with medical innovatorsBreakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.
Hosted by
www.bioworld.com